HOMEVULNERABILITIESCVE-2019-14302
MEDIUM

CVE-2019-14302

NVD-CWE-noinfoPublished: January 10, 2020· Updated: Jun 17, 2026

6.8
CVSS v3.1

Official Description

On Ricoh SP C250DN 1.06 devices, a debug port can be used.

NVD Source

Technical Analysis

CVE-2019-14302 requires local access, meaning attackers must already have a foothold on the target system.

The vulnerability requires no privileges and no user interaction, making it a prime target for automated exploitation campaigns and worm-like propagation.

A successful exploit results in complete confidentiality breach (data exposure), full integrity compromise (data manipulation), availability disruption (denial of service), with a CVSS base score of 6.8.

CVSS v3.1 Vector Breakdown

Exploitability
Attack VectorPhysical
Attack ComplexityLow
Privileges Req.None
User InteractionNone
ScopeUnchanged
Impact
ConfidentialityHigh
IntegrityHigh
AvailabilityHigh
CVSS:3.1/AV:P/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H

Affected Vendors & Products

ricoh121 product(s)
sp c250sf firmwaresp c250sfsp c252sf firmwaresp c252sfsp c250dn firmwaresp c250dnsp c252dn firmwaresp c252dnsp 330sn firmwaresp 330snsp 330sfn firmwaresp 330sfn+109
Source: NVD CPE · 121 total CPE entries

Exploit & PoC Resources

NO KNOWN EXPLOITNo public exploit confirmed at this time
External links open in a new tab. Always verify in a controlled environment before use.

Official Patches & Advisories

All References (4)

http://jvn.jp/en/jp/JVN52962201/index.htmlThird Party Advisory · VDB Entry
http://jvn.jp/en/jp/JVN52962201/index.htmlThird Party Advisory · VDB Entry

Quick Facts

CVE IDCVE-2019-14302
CVSS Score6.8 / 10
SeverityMEDIUM
CISA KEVNo
Affected1 vendor(s)
PublishedJan 10, 2020

Related CVEs (NVD-CWE-noinfo)

Recommended Actions

  • Apply vendor patches immediately
  • Monitor CVE-2019-14302 in threat intel feeds
  • Review IDS/IPS signatures for exploitation attempts
Data sourced from NVD (NIST), CISA KEV, and EPSS (FIRST). Analysis generated by CTIWATCH.COM. CVE data is provided under the NVD usage policy.